Roivant Sciences Officer Eric Venker Files Form 144 to Sell $7.02M in Common Shares

Executive Summary

On October 20, 2026, Eric Venker, an Officer of Roivant Sciences Ltd. (ROIV), filed a Form 144 proposing the sale of 200,000 common shares with an estimated aggregate market value of $7,023,513.39. The proposed sale is executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2026.

Transaction Details

• Securities Offered: 200,000 Common Shares
• Aggregate Market Value: $7,023,513.39
• Implied Price per Share: ~$35.12
• Broker: Rockefeller Financial LLC
• Approximate Sale Date: October 20, 2026
• Source of Shares: Acquired via RSU grant settlements between March 2025 and August 2025.

Historical Context & Trading Activity

In the preceding three months, the reporting person completed multiple sales under the trading plan:

• September 30, 2026: 200,000 shares for $7,323,556.00
• August 28, 2026: 200,000 shares for $7,147,087.91
• August 20, 2026: 13,909 shares for $512,407.56
• July 27, 2026: 200,000 shares for $6,989,924.05

Market Impact & Significance

This filing represents a continuation of programmatic selling under a Rule 10b5-1 plan established in June 2026. While the dollar amount is significant ($7.02M), the pre-scheduled nature of the transactions and consistent monthly pacing moderate the direct signaling impact on company fundamentals.